Pharma group Ipsen replaces CEO over strategic differences

PARIS, Oct 11 (Reuters) - French pharmaceutical company Ipsen IPN.PA said on Monday that it was ditching CEO Jean-Luc Belignard, citing "strategic differences" over the group's development.

He will be replaced by Marc de Garidel, 52, who was formerly a vice-president at biotech company Amgen and started his career at Eli Lilly.

The board said in a statement that it was appointing Garidel, effective Nov. 22, in particular to “carry out the group’s strategy of consolidating its presence in the United States and in emerging countries.”

Ipsen, which specialises in oncology, endocrinology and hematology drugs, has a market capitalisation of roughly 2.1 billion euros. Its shares closed at 25 euros on Monday.